Genedrive plc (GDR) is a commercial-stage biotech focused on point-of-care molecular diagnostics. Its Genedrive® molecular diagnostic platform offers lowcost, simple-to-use devices for highly sensitive and specific testing. The rapid analysis of samples aids real-time decision-making, whether in clinical, public health or biothreat applications. GDR is developing a portfolio of assays for the Genedrive device, with its hepatitis C virus (HCV) and biothreat assays already on the market. The HCV diagnostics market is proving challenging due to a lack of access to HCV drugs, but biothreat revenue should support GDR in fiscal 2020.
05 Feb 2020
Western market progress but developing markets difficult
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Western market progress but developing markets difficult
Genedrive Plc (GDR:LON) | 5.9 0 0.0% | Mkt Cap: 8.41m
- Published:
05 Feb 2020 -
Author:
Martin Hall -
Pages:
8
Genedrive plc (GDR) is a commercial-stage biotech focused on point-of-care molecular diagnostics. Its Genedrive® molecular diagnostic platform offers lowcost, simple-to-use devices for highly sensitive and specific testing. The rapid analysis of samples aids real-time decision-making, whether in clinical, public health or biothreat applications. GDR is developing a portfolio of assays for the Genedrive device, with its hepatitis C virus (HCV) and biothreat assays already on the market. The HCV diagnostics market is proving challenging due to a lack of access to HCV drugs, but biothreat revenue should support GDR in fiscal 2020.